Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study
Nutrition support is recommended in cachexic patients with cancer. However, there is no clear evidence about its impact on tumour growth. Glycolysis, which is usually higher in cancer than normal cells, can be monitored by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging that is widely used for cancer staging and therapy efficacy assessment. Here, we used 18F-FDG PET/CT imaging to investigate whether artificial nutrition has an impact on tumour glucose metabolism in patients with cancer and cachexia.
Source: Clinical Nutrition - Category: Nutrition Authors: Emmanuel Deshayes, H élène de Forges, Julien Fraisse, Marie-Claude Eberlé, Sophie Guillemard, Anne Fallières, Jean-Pierre Pouget, Raphael Tetreau, Pierre-Olivier Kotzki, Lore Santoro, Pierre Senesse, Nicolas Flori Tags: Original article Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Nutrition | Parenteral Nutrition | PET Scan | Study